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Adenovirus-mediated gene transfer into a tumor mass can be improved by combining it with
conditionally-replicating adenovirus (CRAd) when both vectors co-infect the same cancer cell. We
investigated the efﬁciency of enhancing transgene expression and effectiveness of cancer killing of two
advenoviruses (Ads), one expressing E2F-1 (AdE2F-1) and another expressing a truncated form of E2F-1
that lacks the transactivation domain (AdE2Ftr), when combined with oncolytic Adhz60. We found that
AdE2F-1 with Adhz60 actually decreased E2F-1 expression and viral replication through a mechanism
apparently involving repression of the cyclin-E promoter and decreased expression of early and late
structural proteins necessary for viral replication. In contrast, AdE2Ftr with Adhz60 resulted in
increased E2Ftr expression, AdE2Ftr replication, and cancer cell death both in vitro and in vivo. These
results indicate that AdE2Ftr coupled with a CRAd enhances AdE2Ftr-mediated cancer cell death.
& 2012 Elsevier Inc. All rights reserved.Introduction
Inefﬁcient adenovirus-mediated gene transfer to the tumor
mass has been a primary concern in the practical application of
gene therapy. However, new strategies are improving gene trans-
fer and potential therapeutic efﬁcacy. One promising strategy to
increase the therapeutic gene transfer of replication-defective
adenovirus (Ad) is to combine treatment with a conditionally
replicating adenovirus (CRAd).
Previous studies have demonstrated that several cancer cell
lines co-transduced with the replication-enabling plasmid
expressing E1A- and ElA-deleted adenovirus induced the produc-
tion and ampliﬁcation of E1A-deleted adenovirus and its trans-
gene (Dion et al., 1996; Goldsmith et al., 1994). This strategy of
transcomplementation has been widely documented in other cell
types and using multiple different viruses. Recently, the combina-
tion of CRAd with Adp27 was shown to enhance the therapeutic
index of Adp27, resulting in stronger tumor suppression than
treatment with either virus alone (Lee et al., 2006). Another study
showed that transduction of CRAd and an adenovirus expressing
herpes simplex virus thymidine kinase gene (AdHSTK) increased
the transduction efﬁciency of HSTK and increased its sensitivity toll rights reserved.
ry, University of Louisville
. Fax: þ1 502 852 1704.
cMasters).ganciclovir more efﬁciently than AdHSTK alone and resulted in
stronger growth suppression of established lung cancer xenografts
(Oh et al., 2010). Park et al. developed a potent novel genetic
immunotherapy against Lewis lung carcinoma by combining a
CRAd (D24RGD) with a replication-defective adenovirus expressing
interferon-beta (AdIFN-b) (Park et al., 2010).
We and others have previously shown that adenoviral vectors
expressing the transcription factor E2F-1 (AdE2F-1) efﬁciently
induces apoptosis in cancer cells in vitro and in vivo (Dong et al.,
1999, 2002; Elliott et al., 2001; Itoshima et al., 2000; Vorburger
et al., 2005). E2F-1 was ﬁrst described as a transcription factor
that binds to two sites on the adenovirus E2 promoter (Kovesdi
et al., 1986a,b). This binding of E2F-1 to the E2 promoter is
important for expression of viral E2, which is directly involved in
viral DNA replication (Huang and Hearing, 1989). Therefore, we
evaluated whether AdE2F-1 mediated-tumor suppression could
be enhanced by combining treatment with CRAd, and similarly
whether E2F-1 could enhance CRAd replication in cancer cells.
In this study, we evaluated whether transgene expression of
two replication-defective adenoviruses can be increased by
co-infection with E1B-deleted CRAd (Adhz60) in lung cancer cells.
We studied either Ad expressing E2F-1 (AdE2F-1) or a truncated
form of E2F-1 that lacks the transactivation domain (E2Ftr)
(AdE2Ftr) (Bell et al., 2006; Fan and Bertino, 1997). We chose to
study E2Ftr to determine the role it plays in the transactivation
domain of E2F-1 in adenovirus replication. We also investigated
the potential application of this combination strategy to enhance
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found that Adhz60 was unable to support replication of AdE2F-1
and resulted in decreased ectopic expression of E2F-1 and key
proteins required for Adhz60 replication (e.g., cyclin E, E1A,
adenoviral late proteins [ALP]). This effect was associated with
repression of the cyclin E promoter and was independent of
known E2F-1 repressors, such as pRB family members. We found
that AdE2F-1 coupled with Adhz60 resulted in inefﬁcient cancer
cell killing. In contrast, Adhz60 enabled the replication of AdE2Ftr,
resulting in increased E2Ftr expression and, importantly, signiﬁ-
cantly improved the destruction of lung cancer cells in vitro and
in vivo.Results
E2Ftr expression but not E2F-1 expression increased by E1B-deleted
CRAd
According to previous studies, CRAd can support the replica-
tion of replication-defective adenoviruses when co-transduced in
the same cancer cells, resulting in increased transgene expression
from the replication-defective adenovirus (Lee et al., 2006, 2004).
To determine whether the E1B-deleted CRAd (Adhz60) would
support replication of AdE2F-1 or AdE2Ftr to increase their
transgene expression, we transduced A549 lung cancer cells with
AdE2F-1, AdE2Ftr, or AdLacZ (MOI of 25), together with increasing
doses of Adhz60. After 48 h, expression of E2F-1 or E2Ftr was
analyzed by Western blot. Contrary to our expectation, Adhz60
did not increase E2F-1 levels, but did increase E2Ftr expression
(Fig. 1A). As expected, neither E2F-1 nor E2Ftr was detected in
cells co-transduced with control AdLacZþAdhz60. Although E2F-1Fig. 1. Ectopic expression of E2Ftr but not E2F-1 increases viral replication protein expressio
AdLacZ (multiplicity of infecton [MOI] of 25) together with increasing doses of Adhz60.
or AdLacZ (MOI of 25). After 48 h, expression of E2F-1, E2Ftr, cyclin E, adenovirus late p
blot. Images are representative of three separate experiments.expression was not increased, Adhz60 did enable replication of
AdE2Ftr, which may represent a more desirable outcome, in terms
of therapeutic potential, as E2Ftr lacks the oncogenic potential of
E2F-1.
E2F-1 expression is associated with downregulation of cyclin E,
adenovirus late protein (ALP), and E1A expression
In order to determine why E2F-1 levels did not increase in the
presence of Adhz60, we further analyzed expression of viral
proteins important in replication. Previously, we found that cyclin
E expression was required for an efﬁcient adenovirus replication
(Zheng et al., 2008), and that cyclin E was a target gene of E2F-1
(Geng et al., 1996). We found that cyclin E was downregulated in
the presence of overexpressed E2F-1, whereas cyclin E levels were
unaffected by E2Ftr. In fact, cyclin E levels increased in an Adhz60
dose-dependent manner in cells co-infected with AdE2FtrþAdhz60,
with a similar effect observed with co-infection of AdLacZþAdhz60
(Fig. 1A). This result suggests that ectopic expression of E2F-1, but
not E2Ftr, is associated with downregulation of Adhz60 induced-
cyclin E.
We also assessed whether decreased cyclin E levels could affect
expression of ALP, which are required for virion formation and
release. We found that downregulation of cyclin E in the presence
of E2F-1 is associated with decreased ALP levels (Fig. 1A). In
contrast, co-infection with AdE2FtrþAdhz60 or AdLacZþAdhz60
increased ALP expression in an Adhz60 dose-dependent fashion
(Fig. 1A). These data suggest that decreased cyclin E levels in the
presence of E2F-1 are associated with reduced levels of ALP.
Since there is a relationship between E2F-1 and decreased ALP
levels, we next asked whether E2F-1 could also affect early events
in adenovirus replication. A549 cells were infected with Adhz60n in combination with CRAd. (A) A549 cells were infected with AdE2F-1, AdE2Ftr, or
(B) A549 cells were cotransduced with Adhz60 (MOI of 2.5) and AdE2F-1, AdE2Ftr,
roteins, E1A or a-actin (loading control) were detected in cell lysates by Western
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AdLacZ (MOI of 25). After 48 h, expression of E1A (a key protein
for viral replication) was analyzed. We have found that E2F-1 also
was associated with decreased expression of E1A, whereas
neither E2Ftr nor LacZ affected expression of E1A (Fig. 1B).
Collectively, these data suggest that there is an association
between E2F-1 and a decrease of cyclin E, E1A, and ALP proteins.Relationship between E2F-1 and decrease of adenovirus E1A and late
proteins is reproducible in a panel of cancer cells
Next, we wanted to conﬁrm that the association between E2F-1
and cyclin E downregulation was not limited to A549 cells. We
therefore tested the efﬁcacy of Adhz60-induced cyclin E expression
in a panel of cancer cells. Lung cancer cells H1299 and H460, or
osteosarcoma cells Saos2, were infected with Adhz60 (MOI of 2.5),
as described above. Forty-eight hours later, an immunoblot
revealed that infection with Adhz60 induced expression of cyclin
E in all three cell lines (Fig. 2A). In order to determine the effect of
ectopic expression of E2F-1 in these different cancer cell-types,
Adhz60 was infected with AdE2F-1, AdE2Ftr, or AdLacZ. Expression
of cyclin E, E1A, and ALP was analyzed at 48h. As expected, there
was a relationship between E2F-1 and decreased expression of
cyclin E, E1A, and ALP proteins in all cell lines tested (Fig. 2B). In
contrast, neither E2Ftr nor LacZ was associated with decreased
expression of cyclin E, E1A, or ALP (Fig. 2B). These data suggest thatFig. 2. Ectopic expression of E2F-1 but not E2Ftr represses viral replication protein express
Adhz60 (MOI of 2.5). After 48 h, expression of cyclin E was analyzed in cell lysates by W
of 2.5) and AdE2F-1, AdE2Ftr, or AdLacz (MOI of 25). After 48 h, expression of adenoviru
also detected as a loading control. Images are representative of results from three sepE2F-1 expression is associated with decreased expression of cyclin
E, E1A, and ALP in a panel of cancer cells, but E2Ftr expression
allows abundant expression of these viral replication proteins.
Collectively, our data suggested that the combination of AdE2F-1
þAdhz60 would not improve therapeutic efﬁcacy, at least not in
tumors with a similar phenotype to cancer cell lines tested in this
study. This is because there is a close relationship between E2F-1
expression with decreased expression of cyclin E and poor produc-
tion of adenoviral early and late genes. However, we reasoned that
the combination of Adhz60 with AdE2Ftr may have enhanced
therapeutic effects, especially as E2Ftr is a known stronger inducer
of apoptosis than E2F-1 (Gomez-Gutierrez et al., 2010a) and does
not interfere with Adhz60 replication.Decreased Adhz60-induced cyclin E promoter activation is associated
with E2F-1
Because we showed a close relationship between E2F-1 and
decreased expression of cyclin E in the presence of Adhz60, we
assessed whether ectopic expression of E2F-1 might be associated
with repression of cyclin E promoter. A549 cells were transfected
with a plasmid expressing luciferase under regulation of the
cyclin E promoter. This was followed by infection with AdE2F-1,
AdE2Ftr (MOI of 25), Adhz60 (MOI of 2.5) singly, or either AdE2F-1
or AdE2Ftr in combination with Adhz60. After 48 h, luciferase
activity was analyzed. We found that AdE2F-1 alone inducedion in multiple cancer cell lines. (A) H1299, H460, or Saos2 cells were infected with
estern blot. (B) H1299, H460, or Saos2 cells were cotransduced with Adhz60 (MOI
s early and late proteins were detected by Western blot. Expression of a-actin was
arate experiments.
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AdE2Ftr-infected cells. As expected, Adhz60 alone, even at a low
MOI, induced the greatest luciferase activity, indicating activation
of the cyclin E promoter. However, when Adhz60 was combined
with AdE2F-1, luciferase activity declined signiﬁcantly, but was
unaffected by combination of Adhz60 with AdE2Ftr (Po0.05;
Fig. 3A). This result suggests that E2F-1 alone induces cyclin E
promoter activity, but in combination with Adhz60, it may act to
repress activity of adenovirus E2 promoter, resulting in potential
inhibition of Adhz60 replication and lower cyclin E expression.
These results conﬁrm a mechanism of action of E2F-1 that may
make it a less attractive therapeutic option compared with E2Ftr.Fig. 3. Regulation of cyclin E promoter activity by E2F-1. (A) A549 cells were
transfected with cyclin E promoter reporter plasmid followed by no infection
(mock), or infection with AdE2F-1, AdE2Ftr (MOI of 25), Adhz60 (MOI of 2.5) alone,
or either AdE2F-1 or AdE2Ftr in combination with Adhz60. Luciferase activity was
determined at 48h. Results represent the mean of three independent experi-
ments7standard deviation (SD; error bars) (nPo0.05). (B) WT or triple knockout
(TKO) MEF cells were infected with Adhz60 (MOI of 2.5) alone, or in the following
combinations: AdE2F-1þAdhz60, AdE2FtrþAdhz60, or AdLacZþAdhz60. After
48h, expression of cyclin E was analyzed by Western blot. (C) A549 cells were
infected with Adhz69 (MOI of 2.5), AdE2F-1 (MOI of 25) alone or in combination.
After 48 h, expression of E2F-1, cyclin E, E1A, or a-actin were analyzed by Western
blot. Images are representative of results from three separate experiments.pRB family members are not involved in downregulation of cyclin E
in presence of E2F-1
Members of the pRB family exert their cell cycle regulatory
functions by binding and sequestering E2F family of transcription
factors (Dyson, 1998). A combination of pRB and E2F-1 form
transcriptional repressor complexes on promoters of E2F-regulated
genes (Yamasaki et al., 1998). Therefore, pRB family members may
inhibit E2F-1 activity, resulting in repression of E2F-1 target genes.
To test this hypothesis, we used a mouse embryonic ﬁbroblast
(MEF) cell line deﬁcient in pRB, p107, and p130 (three pRB family
members). This was designated as triple knockout (TKO) cells. WT
MEF and TKO MEF were infected as above. At 48h, expression of
cyclin E was analyzed. Interestingly, we observed that there was an
association between E2F-1 expression and decreased cyclin E levels
in both WT and TKO MEF, whereas neither E2Ftr nor LacZ affected
cyclin E levels in either experimental group (Fig. 3B). These results
suggest that E2F-1 is associated with inhibition of Adhz60 induced-
cyclin E, and that pRB family members may not be involved.
Increased expression of E1A does not prevent decrease of cyclin E and
E1A in association with E2F-1
Since we observed that expression of E2F-1 driven by adenovirus
was associated with downregulation of key proteins for CRAd
replication, we next asked whether expression of higher levels of
E1A, driven by a strong cytomegalovirus (CMV) promoter, could
overcome the downregulation of cyclin E and E1A in association
with E2F-1. To do this, we used either A549 cells that were not
infected (mock), or were infected with Adhz69 (MOI of 2.5), a CRAd
that expresses E1A under the regulation of the CMV promoter (Rao
et al., 2004; Zheng et al., 2005), AdE2F-1 (MOI of 25), or AdE2F-1þ
Adhz69. After 48 h, an immunoblot revealed that E2F-1 expression
decreased in cells infected with Adhz69þAdE2F-1, as well as
decreased expression of cyclin E and E1A (Fig. 3C). This result
suggests that, despite E1A expression being driven by a strong CMV
promoter, E2F-1 was still associated with downregulation of key
proteins for CRAd replication.
Combination of AdE2Ftr with Adhz60 increases AdE2Ftr-mediated
cell killing effect
We next evaluated the cell killing potential of combining
replication-defective adenoviral vectors with Adhz60. To study
this, A549 cells were mock-infected or infected with AdE2F-1,
AdE2Ftr, or AdLacZ alone, or in combination with Adhz60. We
then determined cell growth inhibition by MTT assay, assessed
apoptosis by Annexin V staining, and analyzed adenovirus yield.
MTT assay revealed minimal growth inhibition using AdE2F-1,
AdE2Ftr, or AdLacZ alone. There was, however, a signiﬁcant
reduction in the number of viable cells with AdE2FtrþAdhz60
(37% viability) compared with AdE2Ftr or Adhz60 alone (85% or
70% of viability, respectively) (Po0.05) (Fig. 4A). The combination
of AdE2F-1 with Adhz60 was less effective at cell killing (74%
viability); in fact, the combination of AdLacZþAdhz60 induced
greater reduction of viable cells (60%) than AdE2F-1þAdhz60
treatment. This can be explained by replication of both AdLacZ
and Adhz60, which results in higher virus production and onco-
lysis, whereas E2F-1 inhibits virus replication and oncolysis.
Previously, we showed that AdE2Ftr induces apoptosis by
activation of caspase in a panel of cancer cells (Gomez-Gutierrez
et al., 2010a). We therefore conﬁrmed the level of apoptosis by
annexin V staining in experimental groups. We found that AdE2Ftr
or Adhz60 alone induced 8.6% or 18% apoptosis, respectively
(Fig. 4B). The combination of AdE2FtrþAdhz60 induced signiﬁcantly
more apoptosis (43%) compared with either virus alone (Po0.05),
Fig. 4. Effect of combination therapy of AdE2Ftr with Adhz60 on cell killing activity. A549 cells were not infected (mock) or infected with Adhz60 (MOI of 2.5), AdE2F-1,
AdE2Ftr or AdLacZ (MOI of 25) alone, or in the following combinations: AdE2F-1þAdhz60, AdE2FtrþAdhz60, or AdLacZþAdhz60. At 72 h postinfection, the following
assays were performed: (A) Cell growth inhibition measured by MTT assay. (B) Percentage of apoptotic cells was determined by annexin V-PE staining and analyzed as
describe in material and methods. (C) Adenovirus yield in A549 cells at 72 h after infection. Results represent the mean of three independent experiments7standard
deviation (SD; error bars) (*Po0.05).
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apoptosis (Fig. 4B).
The effect of E2F-1 in the release of infectious virus was
measured. Cell culture medium (supernatant) was collected.
Then, virus titers were determined by standard infection unit
measure. We found that titers from cells infected with Adhz60
alone reached 1106 infection units (IFU)/ml. When Adhz60 wasinfected in combination with AdE2F-1, virus titers decreased 10
fold (1105 IFU/ml), whereas titers were similar to the Adhz60
alone levels in cells with combined Adhz60 and AdE2Ftr infection
(Fig. 4C). These data show that oncolytic adenovirus Adhz60
enables replication of AdE2Ftr, which results in enhanced E2Ftr
expression and increased cell-killing effects compared with
AdE2Ftr infection alone.
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of cancer cells
We next tested whether Adhz60 would enable replication of
AdE2Ftr and enhance E2Ftr expression in a panel of cancer cells.
H1299, H460, or Saos2 cell lines were infected with AdE2Ftr (MOI
of 25) alone or in combination with Adhz60 (MOI of 2.5). E2Ftr
expression was analyzed by a Western blot at 48h. We found that
Adhz60 signiﬁcantly enhanced expression of E2Ftr in all three
cancer cell lines tested (Fig. 5A). Next, caspase activity was
assessed; a colorimetric assay for caspase-9 activity revealed that
the combination of AdE2FtrþAdhz60 induced greater caspase-9
activity in comparison with AdE2Ftr alone (Po0.05) (Fig. 5B).
Apoptosis was further validated by annexin V staining, which
revealed that Adhz60 increased AdE2Ftr-mediated apoptosis
(Fig. 5C). These data suggest that oncolytic adenovirus Adhz60
enables AdE2Ftr replication, increases E2Ftr expression, and
induces a higher percentage of apoptosis in a panel of cancer
cells in comparison with AdE2Ftr alone.Fig. 5. Combination therapy effectiveness of AdE2Ftr with Adhz60 on a panel of cancer
cells. (A) H1299, H460, or Saos2 cells were infected with AdE2Ftr (MOI of 25) in the
absence or presence of Adhz60 (MOI of 2.5). After 48 h, expression of E2Ftr, or
a-actin were analyzed byWestern blot. (B) After 48 h of infections above mentioned,
the OD405 values of cell lysates were measured as caspase-9 activity. The results
were expressed as the fold change in treated cells over that of the control cells.
Values represent the mean of three independent experiments7standard deviation
(SD; error bars) (nPo0.05). (C) Percentage of apoptosis determined by annexin V-PE
staining and analyzed as describe in material and methods. Results represent
the mean of three independent experiments7standard deviation (SD; error bars)
(nPo0.05).Combination therapy of AdE2Ftr with Adhz60 induces strong tumor
suppression in vivo
The effectiveness of adenoviral combination therapy was assessed
in vivo using mice bearing ectopic subcutaneous A549 lung tumors.
Balb/c nude mice were injected subcutaneously with 5106 A549
cells. After 6 days, mice with palpable tumors were randomized and
directly injected intratumoraly with AdE2FtrþAdLacZ (control),
AdLacZþAdhz60, or AdE2FtrþAdhz60 (1108 plaque forming units
[pfu] per virus, per mouse) at 0, 2, and 5 days (5 mice per group). In
this experiment, we did not include AdE2F-1, because our in vitro
data showed that the combination of AdE2F-1 with Adhz60 is not
feasible. Tumor volume was measured in two dimensions with
calipers at 5-day intervals after initial adenoviral treatment. There
was a reduction in tumor volume of about 30% in mice treated with
AdLacZþAdhz60 in comparison with control mice injected with
AdE2FtrþAdLacZ (Fig. 6A). However, there was about a 70% decrease
in tumor volume in mice treated with the combination of
AdE2FtrþAdhz60 compared with control (Po0.05; Fig. 6A).
Twenty-ﬁve days after the last adenovirus injection, the tumors
were excised and tumor size between groups was compared visually.
Tumors from mice injected with AdE2FtrþAdLacZ were identiﬁably
larger than tumors from mice injected with AdE2FtrþAdhz60
(Fig. 6B). Additionally, tumors were weighed. Tumors from
AdE2FtrþAdLacZ treatment weighed 1.571.1 g and 0.4570.6 g
from AdLacZþAdhz60 treatment, but AdE2FtrþAdhz60-treated
tumors weighed signiﬁcantly less at 0.0970.25 g compared with
control groups (Po0.05) (Fig. 6C). These results clearly indicate the
improved efﬁcacy of combination therapy of AdE2Ftr with Adhz60
compared with AdE2FtrþAdLacZ.
Tumors were harvested at 25 days after the last adenovirus
injection and subjected to histopathological analysis. Immunohis-
tochemical analysis revealed a strong E2Ftr expression (65% of
positive cells) in tumors of mice injected with AdE2FtrþAdhz60,
which was associated with a signiﬁcant percentage of cleaved
caspase-3-positive cells (70%) (Fig. 6D). In contrast, E2Ftr and
cleaved caspase-3 were not detected in tumors treated with
AdE2FtrþAdLacZ, whereas there was a modest percentage
(37%) of cleaved caspase-3-positive cells in tumors treated with
AdLacZþAdhz60. These results indicate that Adhz60 enhanced and
prolonged expression of E2Ftr, which resulted in strong activation
of caspase-3 in lung tumor mass (Fig. 6D).Discussion
Researchers have long been hampered in their gene transfer
attempts at the successful application of a replication-defective
adenovirus into the tumor mass. This means that several adeno-
viral gene treatments are required to achieve signiﬁcant tumor
mass reduction, which may result in increased adverse effects. In
recent years, combining replication-defective adenovirus with
CRAd has been used to overcome these difﬁculties with promising
experimental results reported (Lee et al., 2006, 2004; Oh et al.,
2010; Park et al., 2010). We proposed that AdE2F-1-mediated
tumor suppression (Dong et al., 1999, 2002; Elliott et al., 2001;
Itoshima et al., 2000; Vorburger et al., 2005) could be enhanced
by combining treatment with CRAd, in that CRAd supplies E1A to
enable AdE2F-1 replication, and AdE2F-1 provides the transcrip-
tion factor to transactivate the CRAd E2 promoter.
Our study was conducted to investigate the potential applica-
tion of the combinational therapy of AdE2F-1 or AdE2Ftr with
Adhz60 (E1B-deleted). Contrary to our expectations, we found
that Adhz60 was unable to support AdE2F-1 replication, as E2F-1
expression did not increase. We suggested that a possible respon-
sible mechanism involves repression of the cyclin E promoter by
Fig. 6. In vivo anti-tumor effect of combination adenoviral therapy. Six days after subcutaneous administration of 5106 A549 cells, mice with palpable tumors were
randomized to receive a local injection of AdE2FtrþAdLacZ, AdLacZþAdhz60, or AdE2FtrþAdhz60 on days 0, 2, and 5 (vertical arrows). The total virus dose was
3 injections at 1108 pfu viral particles. (A) Tumor volume was plotted against time (n¼5 per group) (*Po0.05) (B) On day 25, after last adenovirus treatment tumors
were excised and photographed to show relative tumor size between groups. (C) Tumors were also weighed on day 30. The results are expressed as the mean from each
treatment group7standard error (SE; error bars) (Po0.05). (D) Immunohistochemistry of lung cancer tumors at 25 days after last combination therapy treatment. An mAb
antihuman E2F-1 was used to detect E2Ftr expression and an pAb antihuman cleaved Caspase-3 (Asp175)(5A1E) was used to conﬁrm apoptosis. Photographs were taken
with 20 magniﬁcation and analyzed with NIS-Elements BR 3.0 software (Nikon Instruments, Melville, NY).
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cyclin E, as well as both early and late adenoviral proteins, which
play a key role in adenoviral replication (Zheng et al., 2008). This
effect was reproducible in four separate cancer cell line types
(A549, H1299, H460, Saos2). In contrast, E2Ftr, which lacks the
transactivation domain of E2F-1, did not affect the expression of
these key replication proteins.
E2F-1 has two contrasting functions: it can induce apoptosis
(Dong et al., 2002; Itoshima et al., 2000; Vorburger et al., 2005), or
it can induce progression of the cell cycle (Johnson et al., 1993;Muller and Helin, 2000). It appears, in some circumstances, that
E2F-1 acts as a tumor suppressor gene by downregulation of anti-
apoptotic genes (Dong et al., 1999; Phillips et al., 1999; Yang et al.,
1999, 2000). In other circumstances, it acts as an oncogene by
inducing S-phase entry and cell transformation (Arata et al., 2000;
Xu et al., 1995; Yang and Sladek, 1995). We do not know the
mechanism by which E2F-1 sometimes could act as an oncogene
and in others as a tumor suppressor gene. In addition, binding of
E2F-1 to the E2 promoter is important for expression of viral E2,
which is directly involved in viral DNA replication (Huang and
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appears to have a contradictory effect. Thus, in our case, E2F-1
acts as a tumor suppressor gene, and at high levels, may form
homodimers or heterodimers with other transcription factors, such
as DP-1, and then binds and represses activation of the adenovirus
E2 promoter, thereby in inhibition of CRAd replication.
We previously reported that the construction of adenovirus
expressing E2Ftr under regulation of CMV promoter was unsuc-
cessful, because it was likely that E2Ftr may competitively bind to
the viral E2 promoter and inhibit Ad vector ampliﬁcation (Gomez-
Gutierrez et al., 2010b). However, in our present study, we found
that E2Ftr did not interfere with the CRAd replication process.
These current results further suggest that E2F-1 transactivation
domain may play an important role in the negative regulation of
CRAd E2 promoter. This also suggests that when research is
planned to arm a CRAd with a therapeutic gene, especially a
transcription factor, an assay of transcomplementation should be
performed in order to determine whether such transcription factor
(therapeutic gene) does not interfere with the CRAd replication.
The ideal approach to improve the efﬁcacy of CRAds is to arm
these vectors with therapeutic genes. However, the limited space
in the Ad backbone makes that capacity for packaging transgenes
into CRAds difﬁcult to carry out. To overcome this concern, the
application of replication-defective viruses carrying therapeutic
genes in combination with CRAd vectors expressing E1A in trans
has been proposed (Oh et al., 2010; Park et al., 2010).
In the current study, we show that adenoviral combination
therapy of AdE2Ftr with Adhz60 enhanced E2Ftr expression in
four cancer cell types, but moreover, the AdE2Ftr-mediated
cancer cell death was enhanced by co-infection with Adhz60
in vitro and in vivo. For example, previously, we gave mice four
doses of AdE2Ftr at a higher concentration of 1109 pfu per
treatment (Gomez-Gutierrez et al., 2010a). In the current study,
we gave mice only three doses of AdE2FtrþAdhz60 at a lower
concentration of 1108 pfu for each treatment. Comparing our
results across experiments suggests that, even though we reduced
the total amount of adenovirus 6-fold, we achieved a comparable
anti-tumor effect.
Although co-delivery of two separate vectors provides subopti-
mal therapy, this study was highly useful to determine whether
E2F-1 or E2Ftr is the better option to eventualy arm an oncolytic
adenovirus with a tumor supressor gene, having thus in a single
vector, the properties of oncolysis and apoptosis. We acknowledge
the potential for adverse effects with these therapies, such as
immune reactivity or pre-existing immunity targeting adenoviruses
in humans, and that these effects can render repeated doses of
adenovirus gene therapy vectors less effective. Therefore, we
suggest that it is possible to overcome this concern by the
application of a reduced dose of oncolytic adenovirus armed with
E2Ftr, which may be as effective as multiple other treatments. Thus,
lung cancer tumors could be effectively destroyed through onco-
lysis and apoptosis to achieve therapeutic results. The potential for
augmentation of this gene therapy effect by chemotherapeutic
agents remains to be elucidated as well. The results of the present
studies clearly indicate that combination adenoviral therapy of
AdE2Ftr with CRAd is a promising approach to treat lung cancer.Materials and methods
Cell lines and culture conditions
The human lung cancer cell lines (A549, H1299, H460);
osteosarcoma cell line Saos2; wild-type (WT) and pRB, p107,
and p130 triple-knockout (TKO) mouse embryonic ﬁbroblasts
(MEF); and human embryonic kidney cell line (HEK-293) werepurchased from the American Type Culture Collection (Rockville,
MD). A549, H1299, HEK-293, and TKO MEFs were cultured in
Dulbecco’s Modiﬁed Eagle Medium (DMEM). H460 cells were
cultured in RPMI. Saos2 cells were cultured in McCoy’s medium.
All media were supplemented with 10% heat-inactivated fetal
bovine serum (FBS) and penicillin/streptomycin (100 U/mL). Cell
culture reagents were obtained from Invitrogen (Carlsbad, CA).
Cells were cultured in a 5% CO2 incubator at 37 1C, and the
medium was changed every 2 or 3 days.
Adenoviral vectors and plasmids
All three replication-defective recombinant adenoviral vectors
used in this report have deletion of the viral E1 gene. The
Ad5CMV-E2F-1 (AdE2F-1) and Ad5CMV-LacZ (AdLacZ) vectors
contained the transgenes E2F-1 and nuclear-localized b-galacto-
sidase, respectively, under the control of the CMV promoter, as
previously described (Dong et al., 2002). AdTet-E2Ftr3 (AdE2Ftr)
expressing E2F-1 lacking the transactivation domain was constructed
previously by our laboratory (Gomez-Gutierrez et al., 2010b). Two
CRAds were used, as previously reported by us (Rao et al., 2004;
Zheng et al., 2005): Adhz60 with deletion of E1B gene and Adhz69
expressing E1A under regulation of CMV promoter. The plasmid
containing 2.2 kb of the human cyclin E promoter driving the cDNA
of ﬁreﬂy luciferase was kindly provided by Dr. Greg McCarty (Johns
Hopkins University) (Loeb et al., 2002) and was used to assess the
induction of cyclin E promoter.
Western blot analysis
Cells were harvested and lysed in a radioimmunoprecipitation
assay (RIPA) buffer, as described previously (Gomez-Gutierrez
et al., 2006). Cell lysates were centrifuged and protein concentra-
tion was determined by Detergent Compatible (DC) Protein Assay
(Bio-Rad, Hercules, CA). Equal amounts of cellular protein were
electrophoresed in 10% sodium dodecylsulfate polyacrylamide
gels and transferred to Hybond polyvinylidene diﬂuoride mem-
branes (Amersham, Arlington Heights, IL). The membranes were
ﬁrst incubated with the following primary antibodies (Abs):
mouse-antihuman-E2F-1 monoclonal (m)Ab, rabbit-antihuman
cyclin E (p)Ab (Santa Cruz Biotech, Santa Cruz, CA), rabbit-
antihuman adenovirus proteins virion (Abcam, ab6982, San
Francisco, CA), mouse anti-adenovirus type 5 E1A (BD Pharmingen,
San Diego CA), rabbit-antihuman-a-actin polyclonal (Sigma-Aldrich).
Next, the membranes were incubated with antimouse immunoglo-
bulin (Ig) or anti-rabbit Ig, peroxidase-linked, species-speciﬁc whole
Abs (Amersham, Piscataway, NJ). Electrochemiluminescent reagents
were used to detect the signals, according to the manufacturer’s
instructions (Amersham).
Luciferase-promoter assay
A549 cells were plated in a 12-well plate at 1105 cells/well
and cultured in medium containing 10% FBS. Within 24 h, cells
were co-transfected with a cyclin E promoter construct and a
phRL-CMV plasmid (containing the cDNA encoding Renilla
luciferase) by using Lipofectamine 2000 transfection reagent
(Invitrogen, Carlsbad, CA). Cells were not infected or infected
with AdE2F-1, AdE2Ftr (both MOI of 25), Adhz60 (MOI of 2.5),
Ad-E2F-1þAdhz60, or Ad-E2FtrþAdhz60. After 48 h, lysates were
collected and assayed for luciferase activity using the Dual
Luciferase Reporter Assay System (Progema, Madison, WI), as
reported previously (Hao et al., 2007). Luciferase activity from
untreated control cells was used to determine background signal.
All luciferase values were normalized to the Renilla luciferase
readout values and expressed as relative luciferase activity.
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Cell proliferation was assessed three days after infection by
measuring the conversion of the tetrazolium salt (MTT) to
formazan, according to the manufacturer’s instructions (Sigma-
Aldrich, St Louis, MO), as reported previously (Gomez-Gutierrez
et al., 2010a). The supernatant from each plate was collected for
measurement of absorbance at a wavelength of 570 nm. The
results were expressed as the percentage of live cells.
Annexin V staining
Annexin V staining was performed, as described previously
(Gomez-Gutierrez et al., 2006) and according to the manufac-
turer’s instructions (Annexin V-PE Apoptosis Kit, Pharmingen, San
Diego CA). Cells were analyzed by ﬂuorescence-activated cell
sorter scan (FACScan) ﬂow cytometer (Becton Dickinson, Franklin
Lakes, NJ) with the FlowJo software (Tree Star Inc., Ashland, OR).
Adenovirus titering
1105 cells were plated in a 12-well plate. The next day, cells
were infected with Adhz60 (MOI of 2.5) alone or in combination
with Ad-E2F-1, Ad-E2Ftr, or Ad-LacZ (MOI of 25). Three days after
infection, supernatants were collected. Adenovirus release was
titered by using a TCID50 end-point dilution method in 96-well
plates. In brief, 96-well plates were seeded with 3103 HEK-293
cells and were infected after 48 h with a 3 fold serially diluted
virus. Infected cells were incubated for 7 days, after which wells
with a cytopathic effect were scored visually, and infective unit
(IFU) was calculated as described in Sandig et al., 2000.
Caspase-9 activity assay
1106 cells were not infected (control) or infected with AdE2Ftr
at (MOI of 25) in absence or presence of Adhz60 at MOI of 2.5, 48 h
postinfection. Caspase-9 activity was analyzed by caspase-9 colori-
metric assay kit (R&D Systems, Minneapolis, MN, USA), according to
the manufacturer’s instructions and as described previously (Hao
et al., 2007). No cell lysates and no substrates were used as blanks.
The results were expressed as the fold increase in treated cells over
that of the control cells.
Lung cancer xenograft study
Tumors were formed by subcutaneous (s.c.) injection of 5106
A549 lung cancer cells into bilateral ﬂanks of athymic BALB/c nu/nu
male mice (6–8 weeks-of-age; Charles River Laboratories,
Wilmington, MA). Six days later, mice with palpable tumors were
randomized, and tumors were directly injected with 1108 pfu of
each of: AdLacZþAdE2Ftr (control), AdLacZþAdhz60, or AdE2Ftr
þAdhz60 (n¼5 per group). The puriﬁed virus was diluted in a total
volume of 100 ml of 0.9% of sterile normal saline. Injections were
repeated at days 2 and 5 after initial infection. Tumors were
measured every 3 days, and tumor volume was determined by
externally measuring in 2 dimensions with a caliper. Volume (V)
was determined by the equation V¼(LW2)/2, where L¼ length,
W¼width of the tumor. Animal experiments were performed
in accordance with institutional guidelines and approved by
the University of Louisville Institutional Animal Care and Use
Committee.
Immunohistochemistry
Tumors were excised at 25 days after last adenovirus injection,
ﬁxed in 10% formalin, embedded in parafﬁn blocks, and processedfor histologic analysis and detection of E2Ftr expression and
cleaved caspase-3. A mouse-antihuman-E2F-1 mAb (KH95)
sc-125 (Santa Cruz Biotechnology) at a dilution of 1:200 was
used to detect E2Ftr. A rabbit-antihuman cleaved caspase-3
(Asp175)(5A1E) mAb (Cell Signaling, Danvers, MA) at a dilution
of 1:200 was used to detect cleaved caspase-3. The slides were
then washed with PBS and incubated with the standard ultra-
sensitive ABC peroxidase staining kit (PIERCE, Rockford, IL) and
detected with diaminobenzidine tetrahydrochloride (DAB) solu-
tion containing 0.006% H2O2. Hematoxylin was used as a counter-
stain. Tissue sections stained without primary antibodies were
used as negative controls. Photographs were taken with 20
magniﬁcation and analyzed with NIS-Elements BR 3.0 software
(Nikon Instruments Inc., Melville, NY).
Statistical analysis
The results of the in vitro assays and tumor growth in mice
from three treatment groups were analyzed by the unpaired
Student’s t test using a 1-way ordinary parametric analysis of
variance. Po0.05 was considered statistically signiﬁcant.Acknowledgments
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